Imiquimod (5%) clinical trials

A MultIceNTER Phase I Peptide VaCcine Trial for the Treatment of H3-Mutated Gliomas

This study is testing a new vaccine for adults with a specific type of brain tumour called H3-mutated glioma. It combines a vaccine with standard radiotherapy and another drug called Tecentriq, to see if it's safe and helps the body fight the cancer.